- Conditions
- HIV, Sleep, Smoking Cessation, Cardiovascular Diseases
- Interventions
- Varenicline, Smoking Cessation Counseling, Health Approach 1 to Reduce Smoking, Health Approach 2 to Reduce Smoking
- Drug · Behavioral · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Tucson, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 5,399
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Angina Pectoris
- Interventions
- T89
- Drug
- Lead sponsor
- Tasly Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more
- Conditions
- CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, Laboratory Biomarker Analysis, Palbociclib
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1065
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more
- Conditions
- Asthma
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 2,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 68 more
- Conditions
- B-Cell Malignancies
- Interventions
- Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 337
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip
- Interventions
- Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
- Other · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
- Interventions
- Pharmacokinetic Study, Ulixertinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
- Conditions
- Meningitis, Cryptococcal, HIV Infections
- Interventions
- Flucytosine, Fluconazole, Amphotericin B
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 31 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- tofacitinib, adalimumab, etanercept
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 4,372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more
- Conditions
- Influenza
- Interventions
- Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline
- Biological · Other
- Lead sponsor
- Alachua Government Services, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 3,670 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 34
- States / cities
- Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 543 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 55
- States / cities
- Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
- Conditions
- Peanut Allergy
- Interventions
- AR101
- Biological
- Lead sponsor
- Aimmune Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 47
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
- Conditions
- HPV
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • East Cleveland, Ohio
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab, Irinotecan
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 116
- States / cities
- Tucson, Arizona • Pine Bluff, Arkansas • Bakersfield, California + 104 more
- Conditions
- Urinary Tract Infections, Cystitis
- Interventions
- Sulopenem etzadroxil/probenecid, Amoxicillin/clavulanate
- Drug
- Lead sponsor
- Iterum Therapeutics, International Limited
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 167
- States / cities
- Cullman, Alabama • Saraland, Alabama • Sheffield, Alabama + 126 more
- Conditions
- Mitral Regurgitation
- Interventions
- Transcatheter Mitral Valve Replacement
- Device
- Lead sponsor
- HighLife SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Atlanta, Georgia + 7 more
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- SPYK04
- Drug
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Lone Tree, Colorado • Minneapolis, Minnesota + 6 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma, Recurrent Gastric Carcinoma
- Interventions
- Akt Inhibitor MK2206
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 186
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Tucson, Arizona + 124 more
- Conditions
- Osteoarthritis
- Interventions
- Diclofenac topical sodium gel 1%
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Calera, Alabama • Montgomery, Alabama + 60 more
- Conditions
- Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
- Interventions
- Ad26.COV2.S, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44,325 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 117
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 77 more
- Conditions
- Alzheimer Disease
- Interventions
- Not listed
- Lead sponsor
- Banner Health
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 550 participants
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 1 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- LINX Reflux Management System
- Device
- Lead sponsor
- Ethicon Endo-Surgery
- Industry
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 18 more
- Conditions
- Sleep Initiation and Maintenance Disorders, Insomnia
- Interventions
- GW679769
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 21 more